April 7, 2025 in Press Release

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

Comments Off on HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting Topline data fr ...

Read More
January 13, 2025 in Press Release

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

Comments Off on Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases Research papers focused on the importance of LNP s ...

Read More
December 18, 2024 in Press Release

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

Comments Off on HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers A Phase 1 trial of HF50 to evaluate ...

Read More
Post placeholder image
September 16, 2024 in Press Release

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

Comments Off on Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers The data from the ongoi ...

Read More
Post placeholder image
September 3, 2024 in Press Release

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

Comments Off on HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers The company's groundbreaking immunoliposome, contain ...

Read More
Post placeholder image
June 24, 2024 in Press Release

HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

Comments Off on HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss Preclinical results in naturally occurred diabetic mon ...

Read More
May 28, 2024 in Press Release

HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates

Comments Off on HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates

HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates HFK1 is the company’s groundbreaking dr ...

Read More